Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q3 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $355 thousand versus the consensus estimate of $320 thousand.

Earnings